Starpharma Holdings Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPHRF research report →
Companystarpharma.com
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray.
- CEO
- Cheryl Maley
- IPO
- 2007
- Employees
- 40
- HQ
- Abbotsford, VIC, AU
Price Chart
Valuation
- Market Cap
- $185.21M
- P/E
- -79.73
- P/S
- 18.16
- P/B
- 11.99
- EV/EBITDA
- -30.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 60.11%
- Op Margin
- -100.14%
- Net Margin
- -22.67%
- ROE
- -15.96%
- ROIC
- -25.22%
Growth & Income
- Revenue
- $4.91M · -40.74%
- Net Income
- $-9,990,000 · -22.35%
- EPS
- $-0.02 · -19.50%
- Op Income
- $-11,998,000
- FCF YoY
- 3.75%
Performance & Tape
- 52W High
- $0.53
- 52W Low
- $0.06
- 50D MA
- $0.38
- 200D MA
- $0.24
- Beta
- 0.79
- Avg Volume
- 6.04K
Get TickerSpark's AI analysis on SPHRF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SPHRF Coverage
We haven't published any research on SPHRF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SPHRF Report →